Rocket Pharmaceuticals, Inc. Pre-Tax Income
Rocket Pharmaceuticals, Inc. (RCKT) reported Pre-Tax Income of $131.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was $131.84M.
- Rocket Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-06-30 was -$68.92M.
- Rocket Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$223.12M.
- Rocket Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$258.75M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|
| 2026-06-30 | $131.84M 10-Q · filed 2026-08-10 | $84.24M 10-Q · filed 2026-08-10 | |
| 2025-12-31 | -$223.12M 10-K · filed 2026-02-26 | ||
| 2025-06-30 | -$68.92M 10-Q · filed 2026-08-10 | -$130.25M 10-Q · filed 2026-08-10 | |
| 2024-12-31 | -$258.75M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |